Evidence map›Paper›PMID 36271442›Full record

ArticleAllergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology2022

Plumbagin attenuates Bleomycin-induced lung fibrosis in mice.

Saber Mehdizadeh, Marjan Taherian, Paria Bayati, Kazem Mousavizadeh, Salar Pashangzadeh, Ali Anisian, Nazanin Mojtabavi

Open access · goldAbstract read
In one paragraph

Article in Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. The effect of adrenalectomy on bleomycin-induced pulmonary fibrosis in mice.American journal of physiology. Lung cellular and molecular physiology · 2025
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Saber MehdizadehDepartment of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Marjan TaherianDepartment of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Paria BayatiDepartment of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Kazem MousavizadehDepartment of Pharmacology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Salar PashangzadehDepartment of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Ali AnisianDepartment of Pathology, Islamic Azad University of Abhar, Abhar, Iran.
Nazanin MojtabaviDepartment of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. mojtabavi.n@iums.ac.ir.ORCID http://orcid.org/0000-0002-3539-9483
Iran University of Medical Sciences · IRIslamic Azad University, Abhar Branch · IR

Funding

Iran University of Medical Sciences 96-04-30-32473
6 · The paper itself

Abstract

backgroundIdiopathic pulmonary fibrosis (IPF) is a fatal fibrotic lung disease with limited treatment options. Plumbagin (PL) is an herbal extract with diverse pharmacological effects that have been recently used to treat various types of cancer. This study aims to explore the anti-fibrotic effect of PL and possible underlying mechanisms in IPF.

methodsWe used a bleomycin-induced experimental mouse model of lung fibrosis to assess the potential anti-fibrotic effect of PL. Histological analysis of lung tissue samples by H&E and Masson's trichrome staining and hydroxyproline assay was performed to evaluate the fibrotic alterations. ELISA and real-time quantitative PCR were conducted to determine the amount of tumor necrosis factor-alpha (TNFα), tumor growth factor-beta (TGF-β), connective tissue growth factor (CTGF), and endothelin-1 (ET-1).

resultsBleomycin exposure induced lung fibrosis, which was indicated by inflammation, collagen deposition, and structural damage. PL remarkably prevented bleomycin-induced lung fibrosis. Furthermore, PL significantly inhibited TNF-α and TGF-β production. PL also diminished the upregulated expression of CTGF and ET-1 induced by bleomycin.

conclusionOverall, our findings suggest PL as an anti-fibrotic agent acting via down-regulation of TGF-β/CTGF or ET-1 axis, as well as TNF-α, to improve lung fibrosis.

Indexed as

BleomycinFibrosisIdiopathic pulmonary fibrosisInflammationPlumbagin

Identifiers

PMID36271442
PMCPMC9585773
OpenAlexW4307030501

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.